Chlorothiazide
As of the edition of 20 October 2026, Chlorothiazide is a small molecule: marketed, first approved in 1982 (US); acts on SLC12A3; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Diuril
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 1 region
- Holder of the most recent approval
- Merck & Co.; 3 holders in all
- Registered trials
- 7, 1 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Infections; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A3 | Solute carrier family 12 member 3 | P55017 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 1 | 0 | 1 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Acquired holder | 2008 to now |
| Rising Pharma | Acquired holder | 2023 to now |
| Merck & Co. | Earlier holder |